Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Apitoxin is a new biological drug for pain & inflammation and arthritis, approved by the Korean FDA on May 3, 2003 after 14 years of preclinical, animal, and phase I, II & III clinical studies More
Supercritical fluid crystal and particle engineering to form particles with strong aerodynamic performance and exceptional size uniformity for optimised pulmonary/nasal delivery More
This TACE inhibitory protein could be used as a new therapeutic agent against chronic inflammatory diseases that are mediated by TNF-alpha. More
Improving the reconstitution and increasing the stability of biomolecules using supercritical fluid (SCF) processing More
Specific therapeutic target on platelets for blocking inflammatory diseases of the joint: “collagen microparticle footprint” More
Eicosapentaenoic Acid Triglyceride which can be used for health supplement and treatment for Rheumatoid arthritis More
Rheumatoid arthritis treatment using dendritic cells More
Related Reports
Market Research Reports provided by reports.iptechex.com
Mar 2011 - 23 pages - $5,700
Sep 2008 - $2,500
Nov 2010 - 40 pages - $500
Nov 2010 - 50 pages - $2,000
Jan 2008 - 180 pages - $3,500
Nov 2010 - 1168 pages - $1,495
Oct 2010 - 169 pages - $3,500
Dec 2010 - 84 pages - $500
Oct 2011 - 131 pages - $3,500
Your selection
Browse By
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us